Zeta CD61 Antibody. Zeta’s recombinant mouse antibody recognizes CD61 (GPIIIa), a glycoprotein found on megakaryocytes, platelets and their precursors. CD61 antigen plays a role in platelet aggregation and also as a receptor for fibrinogen, fibronectin, von Willebrand factor and vitronectin. The CD61 antibody will prove useful in detecting neoplastic platelet precursors, normal platelets and most cases of megakaryocytic leukemia.
CD61, also known as GP3A and β3 integrin, is a membrane glycoprotein that associates with CD41 to form a heterodimeric complex with CD41 and is the dominant integrin on platelets that is essential for normal platelet function. CD61 binds to several matrix proteins, including fibrinogen, which is important to blood clotting.
CD61 can promote invasion and migration in tumors. CD61 can be used to identify platelets, megakaryocytes and platelet thrombi and to count platelets in thrombocytopenic patients. CD61 upregulation is related to poor survival on non-small cell lung cancer, breast cancer, cervical cancers, pancreatic ductal adenocarcinomas, T cell acute lymphoblastic leukemia and gliomas.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.